Pfizer Inc. (NYSE:PFE) is navigating a period of strategic upheaval and legal scrutiny as it ends its clinical collaboration ...

Pfizer has reached a $5.4 billion deal to buy Global Blood Therapeutics, a company with one commercialized therapy for sickle cell disease and a pipeline of additional drugs in various stages of ...

Pfizer is making more changes to its marketing partnerships. According to a report from Campaign US, 2 Pfizer will now be working with Publicis for its global creative duties. IPG will still hold ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

Seongnam: SK bioscience, a global vaccine and biotech company, has announced that the Supreme Court of Korea has ruled in its ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

These include the partnership with Haya Karima in ... patients’ lives in the region and beyond”. Pfizer’s recent acquisition of global biotech company Seagen marked the beginning of a ...

Investing.com -- Sangamo's shares have seen a decrease of around 27% in response to Pfizer (NYSE: PFE)'s decision to end the global collaboration and license agreement between the two companies.

“We do not see low-hanging fruit to boost shareholder value,” David Risinger, a Leerink Partners ... Global Market Intelligence. Trained as a veterinarian, Bourla spent much of his career at ...

These include the partnership with Haya Karima in ... change patients' lives in the region and beyond". Pfizer's recent acquisition of global biotech company Seagen marked the beginning of a ...